Tirtha Chakraborty
Chief Tech/Sci/R&D Officer en VOR BIOPHARMA INC. .
Fortuna: 186 929 $ al 31/03/2024
Perfil
Tirtha Chakraborty is currently the Chief Scientific Officer at Vor Biopharma, Inc. since 2020 and an Advisor at Specific Biologics, Inc. since 2023.
Previously, Tirtha held the position of Executive Director & Head-Hematology at CRISPR Therapeutics AG from 2015 to 2018 and Vice President-Cell Therapy Research at Sana Biotechnology, Inc. from 2018 to 2019.
Tirtha obtained a doctorate degree from Tata Institute of Fundamental Research.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
VOR BIOPHARMA, INC.
0.12% | 26/03/2024 | 78 873 ( 0.12% ) | 186 929 $ | 31/03/2024 |
Cargos activos de Tirtha Chakraborty
| Empresas | Cargo | Inicio |
|---|---|---|
| VOR BIOPHARMA INC. | Chief Tech/Sci/R&D Officer | 01/10/2019 |
Specific Biologics, Inc.
 Specific Biologics, Inc. Miscellaneous Commercial ServicesCommercial Services Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead. | Consultant / Advisor | 24/07/2023 |
Antiguos cargos conocidos de Tirtha Chakraborty.
| Empresas | Cargo | Fin |
|---|---|---|
| SANA BIOTECHNOLOGY, INC. | Corporate Officer/Principal | 01/10/2019 |
| CRISPR THERAPEUTICS AG | Director/Board Member | 01/10/2018 |
Formación de Tirtha Chakraborty.
| Tata Institute of Fundamental Research | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| CRISPR THERAPEUTICS AG | Health Technology |
| VOR BIOPHARMA INC. | Health Technology |
| SANA BIOTECHNOLOGY, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Specific Biologics, Inc.
Specific Biologics, Inc. Miscellaneous Commercial ServicesCommercial Services Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead. | Commercial Services |
- Bolsa de valores
- Insiders
- Tirtha Chakraborty
